Published in PLoS One on January 28, 2010
A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One (2012) 1.41
Multiscale models of breast cancer progression. Ann Biomed Eng (2012) 0.91
Ensemble models of neutrophil trafficking in severe sepsis. PLoS Comput Biol (2012) 0.87
Ensembles of signal transduction models using Pareto Optimal Ensemble Techniques (POETs). Biotechnol J (2010) 0.86
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells. Integr Biol (Camb) (2011) 0.85
A systems biology approach to suppress TNF-induced proinflammatory gene expressions. Cell Commun Signal (2013) 0.82
The essential role of Giα2 in prostate cancer cell migration. Mol Cancer Res (2012) 0.78
Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget (2015) 0.78
Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting. Asian J Androl (2016) 0.77
JuPOETs: a constrained multiobjective optimization approach to estimate biochemical model ensembles in the Julia programming language. BMC Syst Biol (2017) 0.75
Development of a diffusion-based mathematical model for predicting chemotherapy effects. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1996) 8.33
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Universally sloppy parameter sensitivities in systems biology models. PLoS Comput Biol (2007) 7.89
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol (2002) 6.68
Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem (1999) 4.19
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol (2009) 3.50
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Statistical mechanical approaches to models with many poorly known parameters. Phys Rev E Stat Nonlin Soft Matter Phys (2003) 3.20
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A (1999) 3.00
A mathematical model of caspase function in apoptosis. Nat Biotechnol (2000) 2.85
Steroid receptor family: structure and functions. Endocr Rev (1990) 2.49
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 2.37
Robustness properties of circadian clock architectures. Proc Natl Acad Sci U S A (2004) 2.31
Downregulation of PP2A(Cdc55) phosphatase by separase initiates mitotic exit in budding yeast. Cell (2006) 2.29
The statistical mechanics of complex signaling networks: nerve growth factor signaling. Phys Biol (2004) 2.24
Systems biology: its practice and challenges. Cell (2005) 2.20
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
Ensemble modeling for analysis of cell signaling dynamics. Nat Biotechnol (2007) 1.84
An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of Neurospora crassa. Proc Natl Acad Sci U S A (2002) 1.82
Control of MAPK signalling: from complexity to what really matters. Oncogene (2005) 1.82
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res (2006) 1.78
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol (1996) 1.75
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (MAPK) pathway model. Biotechnol Prog (2001) 1.71
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A (2006) 1.52
Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J (2000) 1.52
Optimal experimental design for parameter estimation of a cell signaling model. PLoS Comput Biol (2009) 1.47
Network analysis of oncogenic Ras activation in cancer. Science (2007) 1.43
Model identification of signal transduction networks from data using a state regulator problem. Syst Biol (Stevenage) (2005) 1.39
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol (2007) 1.33
Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem (2004) 1.32
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate (2004) 1.29
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res (2003) 1.27
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer (2007) 1.22
Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J Biol Chem (1998) 1.21
Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther (2000) 1.21
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol (2005) 1.21
Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer (1999) 1.15
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem (2004) 1.13
Signaling flux redistribution at toll-like receptor pathway junctions. PLoS One (2008) 1.12
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer (2005) 1.10
A prostate antigen in sera of prostatic cancer patients. Cancer Res (1980) 1.08
Switching Akt: from survival signaling to deadly response. Bioessays (2009) 1.03
Prostatic growth: new insights into hormonal regulation. Br J Urol (1995) 1.03
2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol (2004) 1.01
Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene (2000) 0.98
MAPK cascade possesses decoupled controllability of signal amplification and duration. Biophys J (2004) 0.94
Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst (1982) 0.93
Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells. Cell Biol Int (2000) 0.91
The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol Cell Biol (1988) 0.90
ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene (2003) 0.90
Predicting novel features of toll-like receptor 3 signaling in macrophages. PLoS One (2009) 0.89
Role of the Akt pathway in prostate cancer. Curr Cancer Drug Targets (2009) 0.89
Can complex cellular processes be governed by simple linear rules? J Bioinform Comput Biol (2009) 0.89
Benchmarks for identification of ordinary differential equations from time series data. Bioinformatics (2009) 0.87
Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. Invest Urol (1979) 0.86
Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate (1991) 0.86
A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials. PLoS One (2008) 0.85
Modeling and analysis of the molecular basis of pain in sensory neurons. PLoS One (2009) 0.84
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate (2003) 0.84
Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents (2001) 0.83
Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system. Prostate (1988) 0.78
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
A review of the mammalian unfolded protein response. Biotechnol Bioeng (2011) 1.83
Engineering the spatial organization of metabolic enzymes: mimicking nature's synergy. Curr Opin Biotechnol (2008) 1.76
Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol (2007) 1.33
A dual role for the S-locus receptor kinase in self-incompatibility and pistil development revealed by an Arabidopsis rdr6 mutation. Plant Cell (2009) 1.02
Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. J Biomed Mater Res A (2013) 0.95
Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells. Leuk Lymphoma (2011) 0.92
Multiscale models of breast cancer progression. Ann Biomed Eng (2012) 0.91
Ensembles of signal transduction models using Pareto Optimal Ensemble Techniques (POETs). Biotechnol J (2010) 0.86
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells. Integr Biol (Camb) (2011) 0.85
A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials. PLoS One (2008) 0.85
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. Mol Biosyst (2010) 0.82
The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells. PLoS One (2013) 0.82
Stochastic reaction-diffusion simulation of enzyme compartmentalization reveals improved catalytic efficiency for a synthetic metabolic pathway. Metab Eng (2007) 0.80
Cybernetic model predictive control of a continuous bioreactor with cell recycle. Biotechnol Prog (2003) 0.80
Computational modeling and analysis of insulin induced eukaryotic translation initiation. PLoS Comput Biol (2011) 0.80
Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. J Biol Chem (2014) 0.79
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma (2010) 0.79
Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin. Thromb Res (2009) 0.76
A review of quantitative modeling of B cell responses to antigenic challenge. J Pharmacokinet Pharmacodyn (2014) 0.76
Hierarchical approaches for systems modeling in cardiac development. Wiley Interdiscip Rev Syst Biol Med (2013) 0.75
Optimizing the transient Fast Agro-mediated Seedling Transformation (FAST) method in Catharanthus roseus seedlings. Plant Cell Rep (2013) 0.75